HRP20150327T1 - Kristalni oblici klorovodiäśne soli (4a-r,9a-s)-1-(1h-benzoimidazol-5-karbonil)-2,3,4,4a,9,9a-heksahidro-1h-indeno [2,1-b]piridin-6-karbonitrila i njihova uporaba kao hsd 1 inhibitora - Google Patents
Kristalni oblici klorovodiäśne soli (4a-r,9a-s)-1-(1h-benzoimidazol-5-karbonil)-2,3,4,4a,9,9a-heksahidro-1h-indeno [2,1-b]piridin-6-karbonitrila i njihova uporaba kao hsd 1 inhibitora Download PDFInfo
- Publication number
- HRP20150327T1 HRP20150327T1 HRP20150327TT HRP20150327T HRP20150327T1 HR P20150327 T1 HRP20150327 T1 HR P20150327T1 HR P20150327T T HRP20150327T T HR P20150327TT HR P20150327 T HRP20150327 T HR P20150327T HR P20150327 T1 HRP20150327 T1 HR P20150327T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystalline form
- compound
- powder
- diffraction peaks
- ray diffraction
- Prior art date
Links
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 title 1
- 101100451537 Caenorhabditis elegans hsd-1 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 21
- 238000000634 powder X-ray diffraction Methods 0.000 claims 15
- 239000012458 free base Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 4
- 238000001816 cooling Methods 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 claims 2
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000005588 protonation Effects 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (16)
1. Spoj predstavljen slijedećom strukturnom formulom:
[image]
gdje je barem 50% po masi spoja kristalno.
2. Spoj prema zahtjevu 1, gdje je barem 50% po masi spoja jedan kristalni oblik.
3. Spoj prema zahtjevu 1 ili 2, gdje je barem 99% po masi spoja jedan kristalni oblik.
4. Spoj prema zahtjevu 2 ili 3, gdje je jedan kristalni oblik naznačen sa barem tri pika difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 12.5°, 12.9°, 14.8°, 20.0°, 22.2° i 26.1°; ili 12.5°, 14.8°, 22.2° i 26.1°.
5. Spoj prema zahtjevu 2 ili 3, gdje je jedan kristalni oblik naznačen sa barem četiri pika difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 12.5°, 12.9°, 14.8°, 20.0°, 22.2° i 26.1°; ili barem pet pikova difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 12.5°, 12.9°, 14.8°, 20.0°, 22.2° i 26.1°;
6. Spoj prema zahtjevu 2 ili 3, gdje je jedan kristalni oblik naznačen pikovima difrakcije x-zraka na prahu pri 2Θ kutovima 12.5°, 12.9°, 14.8°, 20.0°, 22.2° i 26.1°; ili 12.5°, 14.8°, 22.2° i 26.1°.
7. Spoj prema zahtjevu 2 ili 3, gdje je jedan kristalni oblik naznačen pikovima difrakcije x-zraka na prahu pri 2Θ kutovima
13.7°, 17.6°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°; ili
13.7°, 17.6°, 19.7, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°; ili
13.7°, 17.6°, 19.7, 20.9, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°; ili
13.7°, 17.6°, 19.3, 19.7, 20.9, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°; ili
13.3°, 13.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°; ili
13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°.
8. Spoj prema zahtjevu 2 ili 3, gdje je jedan kristalni oblik naznačen sa barem sedam pikova difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°; ili
barem osam pikova difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°; ili
barem devet pikova difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°; ili
barem deset pikova difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°; ili
barem jedanaest pikova difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°.
9. Farmaceutski pripravak koji sadrži spoj prema bilo kojem od zahtjeva 1-8 i farmaceutski prihvatljivi nosač ili razrjeđivač.
10. Spoj ili farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, za uporabu u liječenju ili prevenciji bolesti ili stanja na koja se može utjecati inhibiranjem enzima 11β-hidroksisteroid dehidrogenaze (HSD) 1.
11. Spoj prema zahtjevu 10, naznačen time da je bolest ili stanje na koje se može utjecati inhibiranjem enzima 11β-hidroksisteroid dehidrogenaze (HSD) 1 metabolički poremećaj.
12. Postupak proizvodnje kristalnog oblika I spoja predstavljenog slijedećom strukturnom formulom:
[image]
gdje je kristalni oblik I naznačen sa barem tri pika difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 12.5°, 12.9°, 14.8°, 20.0°, 22.2° i 26.1°; ili 12.5°, 14.8°, 22.2° i 26.1°;
koji postupak sadrži:
otapanje slobodne baze spoja u etanolu pri temperaturi ispod 30°C;
protoniranje otopljene slobodne baze sa klorovodičnom kiselinom; te
dopuštanje da se stvori kristalni oblik I hlađenjem otopljene protonirane slobodne baze (npr., pri temperaturi ispod 30°C).
13. Postupak proizvodnje kristalnog oblika II spoja predstavljenog slijedećom strukturnom formulom:
[image]
gdje je kristalni oblik II naznačen sa barem sedam pikova difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°;
koji postupak sadrži:
dovođenje u kontakt spoja sa etanolom kako bi se dobila suspenzija, te
miješanje suspenzije kroz vremenski period dovoljan da se stvori kristalni oblik II.
14. Postupak proizvodnje kristalnog oblika II spoja predstavljenog slijedećom strukturnom formulom:
[image]
gdje je kristalni oblik II naznačen sa barem sedam pikova difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°;
koji postupak sadrži
otapanje spoja u etil acetatu pri temperaturi iznad 40°; te
dopuštanje da se stvori kristalni oblik II hlađenjem otopljenog spoja (npr., pri temperaturi ispod 15°C).
15. Postupak proizvodnje kristalnog oblika II spoja predstavljenog slijedećom strukturnom formulom:
[image]
gdje je kristalni oblik II naznačen sa barem sedam pikova difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°;
koji postupak sadrži:
otapanje slobodne baze spoja u izopropanolu pri temperaturi iznad 40°;
protoniranje slobodne baze klorovodičnom kiselinom; te
dopuštanje da se stvori kristalni oblik II hlađenjem otopljene protonirane slobodne baze (npr., pri temperaturi ispod 15°C).
16. Postupak proizvodnje kristalnog oblika II spoja predstavljenog slijedećom strukturnom formulom:
[image]
gdje je kristalni oblik II naznačen sa barem sedam pikova difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°;
koji postupak sadrži
otapanje slobodne baze spoja u etanolu pri temperaturi iznad 40°;
protoniranje slobodne baze sa klorovodičnom kiselinom i održavanje otopljene protonirane slobodne baze pri temperaturi iznad 40°C kroz barem dva sata; te
dopuštanje da se stvori kristalni oblik II hlađenjem otopljene protonirane slobodne baze (npr., pri temperaturi ispod 15°C).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2010/055586 WO2011057054A1 (en) | 2009-11-06 | 2010-11-05 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline |
US201161484995P | 2011-05-11 | 2011-05-11 | |
PCT/US2011/059331 WO2012061708A1 (en) | 2010-11-05 | 2011-11-04 | Crystalline forms of hydrochloride salt of (4a-r,9a-s) -1- (1h - benzoimidazole- 5 -carbonyl) -2, 3, 4, 4a, 9, 9a - hexahydro -1h- indeno [2, 1 -b] pyridine- 6 -carbonitrile and their use as hsd 1 inhibitors |
EP11785232.7A EP2635563B1 (en) | 2010-11-05 | 2011-11-04 | Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150327T1 true HRP20150327T1 (hr) | 2015-04-24 |
Family
ID=44999935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150327TT HRP20150327T1 (hr) | 2010-11-05 | 2015-03-23 | Kristalni oblici klorovodiäśne soli (4a-r,9a-s)-1-(1h-benzoimidazol-5-karbonil)-2,3,4,4a,9,9a-heksahidro-1h-indeno [2,1-b]piridin-6-karbonitrila i njihova uporaba kao hsd 1 inhibitora |
Country Status (36)
Country | Link |
---|---|
US (2) | US8686149B2 (hr) |
EP (1) | EP2635563B1 (hr) |
JP (1) | JP2013541592A (hr) |
KR (1) | KR20130119939A (hr) |
CN (1) | CN103228642B (hr) |
AP (1) | AP3521A (hr) |
AR (1) | AR083678A1 (hr) |
AU (1) | AU2011323164B2 (hr) |
BR (1) | BR112013011095A2 (hr) |
CA (1) | CA2816136A1 (hr) |
CL (1) | CL2013001221A1 (hr) |
CO (1) | CO6781480A2 (hr) |
CY (1) | CY1116043T1 (hr) |
DK (1) | DK2635563T3 (hr) |
EA (1) | EA022406B1 (hr) |
EC (2) | ECSP12011788A (hr) |
ES (1) | ES2533833T3 (hr) |
GE (1) | GEP20166481B (hr) |
HK (1) | HK1184144A1 (hr) |
HR (1) | HRP20150327T1 (hr) |
IL (1) | IL225647A0 (hr) |
ME (1) | ME02066B (hr) |
MX (1) | MX2013005069A (hr) |
NZ (1) | NZ609281A (hr) |
PE (1) | PE20140123A1 (hr) |
PL (1) | PL2635563T3 (hr) |
PT (1) | PT2635563E (hr) |
RS (1) | RS53900B1 (hr) |
SG (1) | SG189859A1 (hr) |
SI (1) | SI2635563T1 (hr) |
SM (1) | SMT201500095B (hr) |
TN (1) | TN2012000117A1 (hr) |
TW (1) | TWI537258B (hr) |
UA (1) | UA110807C2 (hr) |
UY (1) | UY33701A (hr) |
WO (1) | WO2012061708A1 (hr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2220048B1 (en) | 2007-11-16 | 2017-01-25 | Boehringer Ingelheim International GmbH | Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
US8765780B2 (en) | 2008-05-13 | 2014-07-01 | Boehringer Ingelheim International Gmbh | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use |
US8703765B2 (en) | 2009-06-02 | 2014-04-22 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
EP2440537A1 (en) | 2009-06-11 | 2012-04-18 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
WO2011159760A1 (en) | 2010-06-16 | 2011-12-22 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
TWI537258B (zh) | 2010-11-05 | 2016-06-11 | 百靈佳殷格翰國際股份有限公司 | 六氫茚并吡啶及八氫苯并喹啉之芳基-及雜環芳基羰基衍生物 |
EP2744783A1 (en) | 2011-08-17 | 2014-06-25 | Boehringer Ingelheim International GmbH | Indenopyridine derivatives |
JP2015516404A (ja) * | 2012-05-09 | 2015-06-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝疾患の処置のための合剤 |
EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
EP3935050A4 (en) | 2019-03-06 | 2023-01-04 | C4 Therapeutics, Inc. | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL127995C (hr) | 1963-12-20 | Geigy Ag J R | ||
US3341538A (en) | 1965-06-18 | 1967-09-12 | Geigy Chem Corp | Certain 2, 6-methano-3-benzazocines |
DE1785124A1 (de) | 1968-08-13 | 1971-11-11 | Prym Werke William | Reissverschluss |
DE2108954A1 (en) | 1971-02-25 | 1972-09-07 | Boehringer Sohn Ingelheim | 2-(furylmethyl)-6,7-benzomorphans - useful as cns active agents |
GB1304175A (hr) | 1969-03-31 | 1973-01-24 | ||
DE2105743C3 (de) | 1971-02-08 | 1979-11-29 | Boehringer Sohn Ingelheim | 2-(Furylmethyl)- a -5,9-dialkyl -6,7benzomorphane, Verfahren zu ihrer Herstellung und deren Verwendung |
US3681349A (en) | 1970-03-05 | 1972-08-01 | Morton Norwich Products Inc | 1-(substituted benzyl) tetrahydro-2-(1h) pyrimidones |
US3657257A (en) | 1970-08-31 | 1972-04-18 | Robins Co Inc A H | 3-aryl-8-carbamoyl nortropanes |
DE2229695A1 (de) | 1972-06-19 | 1974-01-31 | Boehringer Sohn Ingelheim | 2-(heteroaryl-methyl)-5,9 beta-dialkyl6,7-benzomorphane, deren saeureadditionssalze sowie verfahren zu deren herstellung |
DE2338369A1 (de) | 1973-07-26 | 1975-02-13 | Schering Ag | Mikrobiologische hydroxylierung von 2,6-methano-3-benzazocinen |
SU510999A3 (ru) | 1973-10-27 | 1976-04-15 | К.Х.Берингер Зон, (Фирма) | Способ получени (метоксиметил-фурилметил)6,7-бензоморфанов илиморфинанов |
US4009171A (en) | 1974-02-21 | 1977-02-22 | Sterling Drug Inc. | N-acylated-11-oxygenated-2,6-methano-3-benzazocine intermediates |
US4087532A (en) | 1974-03-09 | 1978-05-02 | Boehringer Ingelheim Gmbh | Analgesically useful 2-tetrahydrofurfuryl-5-lower alkyl-2-oxy-6,7-benzomorphans and salts thereof |
DE2411382C3 (de) | 1974-03-09 | 1979-09-06 | C.H. Boehringer Sohn, 6507 Ingelheim | 2-Tetrahydrofurfuryl-6,7-benzomorphane, Verfahren zur Herstellung und deren Verwendung |
DE2437610A1 (de) | 1974-08-05 | 1976-02-26 | Boehringer Sohn Ingelheim | Neue 5,9-beta-disubstituierte 2-tetrahydrofurfuryl-6,7-benzomorphane, deren saeureadditionssalze, ihre verwendung als arzneimittel und verfahren zu deren herstellung |
US4108857A (en) | 1975-08-18 | 1978-08-22 | Sterling Drug Inc. | Imidazolylmethyl methanobenzazocines |
DE2828039A1 (de) | 1978-06-26 | 1980-01-10 | Boehringer Sohn Ingelheim | 2-(2-alkoxyethyl)-2'-hydroxy-6,7-benzomorphane deren saeureadditionssalze diese enthaltende arzneimittel und verfahren zu deren herstellung |
GB9510459D0 (en) | 1995-05-24 | 1995-07-19 | Zeneca Ltd | Bicyclic amines |
GB9517622D0 (en) | 1995-08-29 | 1995-11-01 | Univ Edinburgh | Regulation of intracellular glucocorticoid concentrations |
US6251897B1 (en) | 1996-07-31 | 2001-06-26 | Nikken Chemicals Co., Ltd | 6-phenyltetrahydro-1,3-oxazin-2-one derivative and pharmaceutical composition containing the same |
GB9623944D0 (en) | 1996-11-15 | 1997-01-08 | Zeneca Ltd | Bicyclic amine derivatives |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
WO2001055063A1 (fr) | 2000-01-25 | 2001-08-02 | Idemitsu Petrochemical Co., Ltd. | Nouveaux composes a base de bisadamantane, procedes de production et nouveaux derives de bisadamantane |
DE10034623A1 (de) | 2000-07-17 | 2002-01-31 | Bayer Ag | Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren |
EP1506174B1 (en) | 2002-05-17 | 2015-09-30 | Taiwanj Pharmaceuticals Co., Ltd. | Use of naltrexone for treating kidney and liver damage |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
ATE474577T1 (de) | 2003-03-26 | 2010-08-15 | Merck Sharp & Dohme | Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten |
EP1787982B1 (en) * | 2003-04-11 | 2010-05-12 | High Point Pharmaceuticals, LLC | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds |
US7700583B2 (en) | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
NZ551076A (en) | 2004-05-07 | 2009-05-31 | Janssen Pharmaceutica Nv | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
ES2334246T3 (es) | 2004-08-30 | 2010-03-08 | Janssen Pharmaceutica Nv | Derivados triciclos de adamantilamida como inhibidores de la 11-beta-hidroxiesteroide-deshidrogenasa. |
WO2006040329A1 (en) | 2004-10-12 | 2006-04-20 | Novo Nordisk A/S | 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds |
CA2581745A1 (en) | 2004-10-13 | 2006-04-27 | Neurogen Corporation | Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor |
WO2006104280A1 (ja) | 2005-03-31 | 2006-10-05 | Takeda Pharmaceutical Company Limited | 糖尿病の予防・治療剤 |
CN101355938A (zh) | 2005-11-01 | 2009-01-28 | 高点制药有限责任公司 | 取代的酰胺的药学应用 |
US20090124598A1 (en) | 2005-11-01 | 2009-05-14 | Henrik Sune Andersen | Pharmaceutical use of substituted amides |
JP2007140188A (ja) | 2005-11-18 | 2007-06-07 | Fujifilm Corp | ポジ型感光性組成物及びそれを用いたパターン形成方法 |
WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
CA2635087A1 (en) | 2005-12-30 | 2007-07-19 | Merck & Co., Inc. | Cholesteryl ester transfer protein inhibitors |
EP1979318A1 (en) | 2006-01-31 | 2008-10-15 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
WO2007124337A1 (en) | 2006-04-21 | 2007-11-01 | Eli Lilly And Company | Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1 |
PL2029529T3 (pl) | 2006-04-24 | 2010-11-30 | Lilly Co Eli | PODSTAWIONE PIROLIDYNONY JAKO INHIBITORY DEHYDROGENAZY 11-ß-HYDROKSYSTEROIDOWEJ TYPU 1 |
WO2007127763A2 (en) | 2006-04-25 | 2007-11-08 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
PE20080344A1 (es) | 2006-06-27 | 2008-06-09 | Sanofi Aventis | Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1 |
US8132151B2 (en) | 2006-07-18 | 2012-03-06 | Yahoo! Inc. | Action tags |
JP5079011B2 (ja) | 2006-10-19 | 2012-11-21 | エフ.ホフマン−ラ ロシュ アーゲー | 糖尿病のための11β−HSD1阻害剤としてのイミダゾロン及びイミダゾリジノン誘導体 |
TW200829171A (en) | 2006-11-17 | 2008-07-16 | Nihon Nohyaku Co Ltd | Haloalkyl sulfonanilide derivatives or salts thereof, herbicide using it as effective constituent and use-method thereof |
EP1935420A1 (en) | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors |
WO2008106128A2 (en) | 2007-02-26 | 2008-09-04 | Vitae Pharmaceuticals, Inc. | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 |
CN101652359A (zh) | 2007-03-09 | 2010-02-17 | 高点制药有限责任公司 | 作为羟类固醇脱氢酶抑制剂的吲哚-和苯并咪唑酰胺类 |
ES2395081T3 (es) | 2007-07-26 | 2013-02-08 | Vitae Pharmaceuticals, Inc. | Síntesis de inhibidores de la 11beta-hidroxiesteroide deshidrogenasa de tipo 1 |
AR069207A1 (es) | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
EP2220048B1 (en) * | 2007-11-16 | 2017-01-25 | Boehringer Ingelheim International GmbH | Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
WO2009102428A2 (en) | 2008-02-11 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 |
EP2245014B1 (en) * | 2008-02-12 | 2011-11-02 | Boehringer Ingelheim International GmbH | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
WO2009102460A2 (en) | 2008-02-15 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
CA2718264A1 (en) | 2008-03-18 | 2009-09-24 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
EP2300461B1 (en) | 2008-05-01 | 2013-04-17 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
JP5538365B2 (ja) | 2008-05-01 | 2014-07-02 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤 |
JP5777030B2 (ja) | 2008-07-25 | 2015-09-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の阻害剤 |
RU2539979C2 (ru) | 2008-07-25 | 2015-01-27 | Вайтаи Фармасьютиклз, Инк. | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 |
US8057970B2 (en) | 2008-09-01 | 2011-11-15 | D2S, Inc. | Method and system for forming circular patterns on a surface |
UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
TWI531571B (zh) * | 2009-11-06 | 2016-05-01 | 維它藥物公司 | 六氫茚并吡啶及八氫苯并喹啉之芳基-及雜芳基羰基衍生物 |
TWI537258B (zh) | 2010-11-05 | 2016-06-11 | 百靈佳殷格翰國際股份有限公司 | 六氫茚并吡啶及八氫苯并喹啉之芳基-及雜環芳基羰基衍生物 |
-
2011
- 2011-10-18 TW TW100137675A patent/TWI537258B/zh not_active IP Right Cessation
- 2011-11-01 AR ARP110104053A patent/AR083678A1/es unknown
- 2011-11-01 UY UY0001033701A patent/UY33701A/es not_active Application Discontinuation
- 2011-11-04 SI SI201130449T patent/SI2635563T1/sl unknown
- 2011-11-04 SG SG2013026430A patent/SG189859A1/en unknown
- 2011-11-04 AU AU2011323164A patent/AU2011323164B2/en not_active Ceased
- 2011-11-04 JP JP2013537864A patent/JP2013541592A/ja active Pending
- 2011-11-04 ES ES11785232.7T patent/ES2533833T3/es active Active
- 2011-11-04 EA EA201390643A patent/EA022406B1/ru not_active IP Right Cessation
- 2011-11-04 RS RS20150205A patent/RS53900B1/en unknown
- 2011-11-04 MX MX2013005069A patent/MX2013005069A/es unknown
- 2011-11-04 NZ NZ609281A patent/NZ609281A/en not_active IP Right Cessation
- 2011-11-04 EP EP11785232.7A patent/EP2635563B1/en active Active
- 2011-11-04 WO PCT/US2011/059331 patent/WO2012061708A1/en active Application Filing
- 2011-11-04 AP AP2013006902A patent/AP3521A/xx active
- 2011-11-04 US US13/289,418 patent/US8686149B2/en active Active
- 2011-11-04 KR KR1020137014295A patent/KR20130119939A/ko not_active Application Discontinuation
- 2011-11-04 UA UAA201307042A patent/UA110807C2/uk unknown
- 2011-11-04 DK DK11785232.7T patent/DK2635563T3/en active
- 2011-11-04 CA CA2816136A patent/CA2816136A1/en not_active Abandoned
- 2011-11-04 PE PE2013000949A patent/PE20140123A1/es not_active Application Discontinuation
- 2011-11-04 GE GEAP201113105A patent/GEP20166481B/en unknown
- 2011-11-04 PL PL11785232T patent/PL2635563T3/pl unknown
- 2011-11-04 ME MEP-2015-42A patent/ME02066B/me unknown
- 2011-11-04 PT PT117852327T patent/PT2635563E/pt unknown
- 2011-11-04 BR BR112013011095A patent/BR112013011095A2/pt not_active IP Right Cessation
- 2011-11-04 CN CN201180053044.5A patent/CN103228642B/zh not_active Expired - Fee Related
-
2012
- 2012-03-16 TN TNP2012000117A patent/TN2012000117A1/en unknown
- 2012-04-05 EC ECSP12011788 patent/ECSP12011788A/es unknown
-
2013
- 2013-04-09 IL IL225647A patent/IL225647A0/en unknown
- 2013-05-03 CL CL2013001221A patent/CL2013001221A1/es unknown
- 2013-05-30 CO CO13132839A patent/CO6781480A2/es active IP Right Grant
- 2013-06-05 EC ECSP13012664 patent/ECSP13012664A/es unknown
- 2013-10-15 HK HK13111568.4A patent/HK1184144A1/xx not_active IP Right Cessation
-
2014
- 2014-02-26 US US14/190,899 patent/US9120769B2/en active Active
-
2015
- 2015-02-25 CY CY20151100195T patent/CY1116043T1/el unknown
- 2015-03-23 HR HRP20150327TT patent/HRP20150327T1/hr unknown
- 2015-04-16 SM SM201500095T patent/SMT201500095B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150327T1 (hr) | Kristalni oblici klorovodiäśne soli (4a-r,9a-s)-1-(1h-benzoimidazol-5-karbonil)-2,3,4,4a,9,9a-heksahidro-1h-indeno [2,1-b]piridin-6-karbonitrila i njihova uporaba kao hsd 1 inhibitora | |
HRP20191655T1 (hr) | N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilat sol | |
HRP20191597T1 (hr) | Kristalni derivat 6,7-nezasićenog-7-karbamoil morfinana i postupak za njegovu proizvodnju | |
SG10201407881WA (en) | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase | |
EP1993513A4 (en) | METHOD AND DEVICE FOR PREPARING CRYSTALLINE ORGANIC MICROPARTICLE COMPOSITIONS USING MICROMATES AND CRYSTALLIZING MICROSAMEN AND THEIR USE | |
HRP20151344T1 (hr) | Kristalni oblik slobodne baze bifenilnog spoja | |
ATE484504T1 (de) | Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika | |
JP2013541592A5 (hr) | ||
JP5979376B2 (ja) | 溶解性の高いピロロキノリンキノン塩及びその製造方法 | |
IL216427A (en) | Solid Pharmaceutical Components of 4 - {[9-Chloro-7- (2-Fluoro-6-Methoxyphenyl) - h5- Pyrimido [d-5,4] [2] Benzazepine-2-ram] Amino} -2-Acid Oxidizer Benzoic, its salts and processes for making them | |
WO2010007316A3 (fr) | NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
NZ598467A (en) | Stable sns-595 compositions and methods of preparation | |
BRPI0605893A (pt) | composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina | |
WO2011050054A3 (en) | Coumarin compounds as receptor modulators with therapeutic utility | |
NZ601998A (en) | Substituted aza-bicyclic imidazole derivatives useful as trpm8 receptor modulators | |
EP2749562A1 (en) | Fused heterocyclic derivative and pharmaceutical use thereof | |
WO2013024358A3 (en) | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors | |
US8975255B2 (en) | Preparation and pharmaceuticals of biphenyl benzamide-derived derivatives | |
HRP20160363T1 (hr) | Soli desfesoterodina | |
TH135901B (th) | ตัวยับยั้งกลูโคซิลเซอราไมด์ ซินเธส | |
TH135901A (th) | ตัวยับยั้งกลูโคซิลเซอราไมด์ ซินเธส | |
TH84282A (th) | เฮทเทอโรไซเคิลในรูปนิโคทินิค แอซิด รีเซปเตอร์ อะโกนิสท์สำหรับการรักษาภาวะไขมันในเลือดผิดปกติ | |
HRP20140839T1 (hr) | Postupak sinteze ivabradina i njegovih adicijskih soli i farmaceutski prihvatljivih kiselina | |
SA519410385B1 (ar) | مـــركب حلقي غير متجانس | |
Prlić Kardum et al. | The influence of additives and seeding on glycine crystal characteristics |